NRIX

Nurix Therapeutics, Inc. Common stock

15.67

USD

NRIX Earnings Reports

Positive Surprise Ratio

NRIX beat 10 of 22 last estimates.

45%

Next Report

Date of Next Report

Apr 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$15.99M

-$0.76

Implied change from Q4 25 (Revenue/ EPS)

+17.79%

-7.32%

Implied change from Q1 25 (Revenue/ EPS)

-13.33%

+13.43%

Nurix Therapeutics, Inc. Common stock earnings per share and revenue

On Jan 28, 2026, NRIX reported earnings of -0.82 USD per share (EPS) for Q4 25, beating the estimate of -0.88 USD, resulting in a 7.66% surprise. Revenue reached 13.58 million, compared to an expected 14.60 million, with a -6.98% difference. The market reacted with a +3.52% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.76 USD, with revenue projected to reach 15.99 million USD, implying an decrease of -7.32% EPS, and increase of 17.79% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Nurix Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Nurix Therapeutics, Inc. Common stock reported EPS of -$0.82, beating estimates by 7.66%, and revenue of $13.58M, -6.98% below expectations.

How did the market react to Nurix Therapeutics, Inc. Common stock's Q4 2025 earnings?

The stock price moved up 3.52%, changed from $18.75 before the earnings release to $19.41 the day after.

When is Nurix Therapeutics, Inc. Common stock expected to report next?

The next earning report is scheduled for Apr 06, 2026.

What are the forecasts for Nurix Therapeutics, Inc. Common stock's next earnings report?

Based on 10 analysts, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.76 and revenue of $15.99M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.